WHITE PAPER
Paradigm Shifts in Early Phase Non-Oncology Studies in Healthy Volunteers and Patients
Jul 10, 2023

Drug development has undergone significant changes in recent years, particularly in the design and conduct of early phase (Phase 1/2a) non-oncology clinical studies. The goal of these changes has been to accelerate the early clinical drug development process, ensure safer decision-making, and deliver potential new medicines to patients sooner. In this white paper, we explore the factors that have driven these changes, analyze their impact on the design and execution of these studies, and examine the challenges that clinical researchers are facing.

Related solutions

Contact Us